← 返回

异体间充质干细胞接种 NeuraGen 神经导管的兔模型安全性

英文原题:Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen Nerve Guides in a Rabbit Model.

查看英文原题

Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen Nerve Guides in a Rabbit Model.

PubMed 2023/02/01(内容时间) Tissue Eng Part C Methods Q3 · IF 2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

间充质干细胞(MSC)可促进神经和组织再生,已具备向临床转化的潜力。自体MSC的应用受到多项因素限制,包括需及时采集、需经增殖扩增以增加细胞数量,以及细胞老化或病理状况可能降低其再生潜能。由于MSC具有免疫特权性,异体MSC可作为“现货型”细胞重建疗法,用于支持神经修复。

因此,研究者在兔模型中评估了接种异体MSC的NeuraGen神经导管(NNG)的安全性和免疫反应指标。研究将接种或未接种异体兔MSC的NNG用于兔坐骨神经。随机分组包括I组(未手术对照,n=3)以及II、III组(坐骨神经分别包裹未接种或接种异体MSC的NNG;每组n=5)。两周后处死兔,通过坐骨神经和胫骨前肌(TA)的组织学评估监测功能恢复。通过评估体重、组织重量、体温及血液学指标(包括白细胞计数(WBC)、脾脏组织学以及CD4⁺和CD8⁺ T淋巴细胞)分析宿主对异体MSC的反应。神经和脾脏组织学检查均未见明显异常,与异体MSC给药后未发生显著全身或局部免疫反应相符。未接种组与接种组之间的WBC或CD4⁺、CD8⁺ T淋巴细胞均无显著差异。

因此,异体MSC用于此类研究是安全的;在转化动物研究中,可考虑以异体MSC替代自体MSC,为未来临床神经修复策略奠定基础。影响说明:已有报告显示,自体间充质干细胞(MSC)与神经移植物替代物联合使用可增强神经再生。

然而,自体干细胞来源会延迟治疗,并可能受到年龄或疾病相关功能障碍的影响。本研究在兔模型中调查了异体MSC的安全性以及神经导管递送的最佳细胞数量。与未接种神经导管相比,接种异体MSC的导管未诱发全身或局部免疫反应。研究结果最终有望推动通用供者细胞疗法临床转化,用于神经缺损修复。

展开英文摘要原文

Mesenchymal stem cells (MSCs) stimulate nerve and tissue regeneration and are primed for clinical translation. Application of autologous MSCs is limited by requirements for expedient harvesting procedures, proliferative expansion to increase number of cells, and reduced regenerative potential due to aging or pathological conditions. Because MSCs are immune privileged, allogeneic MSCs may serve as "off-the-shelf" cell-based reconstructive treatments to support nerve repair.

Therefore, we examined the safety and immune response parameters of allogeneic MSCs seeded on NeuraGen Nerve Guides (NNGs) in a rabbit model. NNGs with or without allogeneic rabbit MSCs were applied to rabbit sciatic nerves. Randomly assigned treatment included group I (no surgery control, n = 3) or groups II and III (sciatic nerve wrapped with unseeded or allogeneic MSC-seeded NNGs; n = 5/group). Rabbits were euthanized after 2 weeks to monitor functional recovery by histological evaluation of sciatic nerves and tibialis anterior (TA) muscle.

Host reactions to allogeneic MSCs were analyzed by assessment of body and tissue weight, temperature, as well as hematological parameters, including white blood cell count (WBC), spleen histology, and CD4 + and CD8 + T lymphocytes. Histological analyses of nerves and spleen were all unremarkable, consistent with absence of overt systemic and local immune responses upon allogeneic MSC administration. No significant differences were observed in WBC or CD4 + and CD8 + T lymphocytes across unseeded and seeded treatment groups.

Thus, allogenic MSCs are safe for use and may be considered in lieu of autologous MSCs in translational animal studies as the basis for future clinical nerve repair strategies. Impact statement Autologous mesenchymal stem cells (MSC) have been reported to enhance nerve regeneration when used in conjunction with nerve graft substitutes.

However, autologous stem cell sources delay treatment and may be susceptible to age- or disease-related dysfunctions. In this study, we investigated the safety of allogeneic MSCs and the optimal number of cells for nerve conduit delivery in a rabbit model. When compared with unseeded nerve conduits, allogeneic MSC-seeded conduits did not induce a systemic or local immune response. The findings of this study will ultimately facilitate the clinical translation of a universal donor cell-based treatment option for nerve defects.

论文信息

作者
Bedar M、van Wijnen AJ、Shin AY
单位
Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Tissue engineering. Part C, Methods2023 Feb
原文标识
PubMed 36680753 · DOI 10.1089/ten.TEC.2022.0159